Published in Indian J Nephrol on November 01, 2013
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 1.29
Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (2010) 1.15
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant (2009) 1.10
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 1.09
The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation (2010) 0.93
Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Pharmacoeconomics (2003) 0.82
Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation. Transplant Proc (2003) 0.81
Efficacy of basiliximab induction in poorly matched living donor renal transplantation. Indian J Nephrol (2013) 0.80
A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant (2000) 0.80